Basecamp Wealth Advisors’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$407K Sell
10,728
-230
-2% -$10.6K 0.09% 111
2026
Q2
$525K Sell
10,958
-610
-5% -$26.2K 0.1% 122
2026
Q1
$425K Sell
11,568
-58
-0.5% -$2.75K 0.09% 141
2025
Q4
$592K Buy
+11,626
New +$595K 0.13% 95

Other funds holding NVO

Basecamp Wealth Advisors's NVO Position: Q3 2026 in Review

Basecamp Wealth Advisors reduced its Novo Nordisk (NVO) stake by 2.1% in Q3 2026, selling an estimated $10.6K and leaving 10,728 shares worth $407K. The position accounts for 0.09% of the portfolio, ranked #111.

Basecamp Wealth Advisors first reported a position in NVO in Q4 2025 and has held it in 4 quarters since. The position peaked at $592K in Q4 2025. 1,237 funds tracked by Wall St. Rank hold NVO as of Q3 2026.

  • Basecamp Wealth Advisors held 10,728 shares of Novo Nordisk worth $407K as of Q3 2026.
  • Basecamp Wealth Advisors sold 230 Novo Nordisk shares in Q3 2026, an estimated $10.6K.
  • Novo Nordisk made up 0.09% of Basecamp Wealth Advisors's portfolio in Q3 2026, its #111 holding.
  • Basecamp Wealth Advisors first reported a position in Novo Nordisk in Q4 2025 and has held it in 4 quarters since.
  • Basecamp Wealth Advisors's Novo Nordisk position peaked at $592K in Q4 2025.
  • 1,237 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.